Eupraxia Pharmaceuticals (EPRX) Net Equity Issued and Repurchased (2024)
Eupraxia Pharmaceuticals' (EPRX) quarterly Net Equity Issued and Repurchased came in at $22.9 million in Q1 2024.
Eupraxia Pharmaceuticals (EPRX) Net Equity Issued and Repurchased (2024) Analysis & Trends
Eupraxia Pharmaceuticals (EPRX) has 1 years of Net Equity Issued and Repurchased data on file, last reported at $22.9 million in Q1 2024.
- On a quarterly basis, Net Equity Issued and Repurchased changed N/A year-over-year to $22.9 million in Q1 2024; TTM through Dec 2024 was $22.9 million, a N/A change from a year earlier, with the FY2025 full-year figure at $73.9 million, up 223.33% from the prior year.
- Net Equity Issued and Repurchased for Q1 2024 stood at $22.9 million.
- Over the last five years, Net Equity Issued and Repurchased for EPRX reached as high as $22.9 million in Q1 2024 and fell as low as $22.9 million in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 163.10 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 141.90 Mn |
| 10 | Eupraxia Pharmaceuticals | 357.29 Mn | 355.69 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | 22.85 Mn |
| Mar 31, 2024 | 22.85 Mn |